AlphaFold2 examples from CASP 14: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Eric Martz (talk | contribs) No edit summary |
Eric Martz (talk | contribs) No edit summary |
||
| Line 18: | Line 18: | ||
===ORF8 is not a novel fold=== | ===ORF8 is not a novel fold=== | ||
Less than 2% of new [[empirically-determined structures]] have novel folds; that is, folds not aready represented in the [[PDB]]<ref name="cath2011">PMID: 21097779</ref>. When chain A of [[7jx6]] was submitted to Dali<ref name="dali2020">PMID: 31606894</ref> (February, 2021), the top hit was | Less than 2% of new [[empirically-determined structures]] have novel folds; that is, folds not aready represented in the [[PDB]]<ref name="cath2011">PMID: 21097779</ref>. When chain A of [[7jx6]] was submitted to Dali<ref name="dali2020">PMID: 31606894</ref> (February, 2021), the top hit was the N-terminal domain of two domains in [[5a2f]], the CD166 human cell surface receptor involved in activation of T lymphocytes. The Z-score was 7.1, and 88 alpha carbons aligned with RMSD 3.2 Å. Dali reported the identity as 6% in a structure-based sequence alignment. Sequence alignment by MAFFT<ref name="mafft">PMID: 23329690</ref> obtained 18% sequence identity using more and larger gaps. | ||
===AlphaFold2 Prediction for ORF8=== | ===AlphaFold2 Prediction for ORF8=== | ||
